The HER receptor family: a rich target for therapeutic development.
about
Antibody-based imaging of HER-2: moving into the clinic.EGFR associated expression profiles vary with breast tumor subtypeSystem theoretical investigation of human epidermal growth factor receptor-mediated signalling.Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancerPrognostic biomarkers in ovarian cancer.The HER family and cancer: emerging molecular mechanisms and therapeutic targets.Systems biology and genomics of breast cancer.The SCHOOL of nature: III. From mechanistic understanding to novel therapiesHER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptorSerum organochlorines and breast cancer: a case-control study among African-American womenThe emerging role of the PI3-K-Akt pathway in prostate cancer progression.Molecular diagnostics as a tool to personalize treatment in adult glioma patients.Epidermal growth factor receptor-targeted agents for lung cancer.Protein-based tumor molecular imaging probes.Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas.Multimodality imaging of the HER-kinase axis in cancer.Erlotinib in non-small-cell lung cancer.Labeling and Biological Evaluation of (99m)Tc-HYNIC-Trastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer.Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.Cancer therapy using tumor-associated antigens to reduce side effects.Molecular imaging with SERS-active nanoparticles.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.Induction of ERBB2 nuclear transport after radiation in breast cancer cells.Epidermal growth factor receptor expression in feline oral squamous cell carcinomas.Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging.High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.
P2860
Q30423880-87758F71-EBC6-4798-A531-B9028AF5458BQ33292502-C923E13A-CDF1-4B1D-ACAD-198F7046270BQ33388432-51494284-1907-4558-B908-ED7246D6EFD8Q33582990-058B9742-ACC4-46F0-8A0B-364AE52C44A5Q34086636-37CE70AF-18F1-49E1-BA76-726DE1941DF9Q34558080-05464A5E-3D59-4D41-8CE7-686D1C75374EQ34576377-72C97E3C-A49F-434C-939E-281DA45B3B62Q34619705-EC1173AA-87BB-4F06-B063-1BE76E1E0805Q34974682-6240DE1A-A151-40DF-8919-CA3E5D3B7C98Q35234141-98ABB764-9540-4BBB-B7A3-F8755FDC2577Q35728963-5296D68B-2D0D-4A1D-B5F4-05509E3A8B6AQ36050987-127E5AE5-F161-40EA-A2DD-848859B5059FQ36478647-31F5175D-4F20-45AF-8CF5-ED256C24D9C6Q36493232-F6C66AA1-6B42-4F17-ADF1-AE46A87032AFQ36742911-00C65D59-D459-41AA-9089-3CC685B7FBA9Q36787372-E38183C5-C9CA-4E45-9A8C-841B95BEC6F5Q36936796-058F4071-3B42-4EDB-9904-E02C59622955Q36968183-C6DD2FCA-DA2B-4BCD-A785-DEE154C394CFQ37100372-7B8DABA4-14C9-41B9-A267-E20EBE7F0BD0Q37220415-EC46CD32-3010-4357-88F1-5B2C735F44D6Q37320501-85A60C6D-971C-4E8F-9399-DA2918444CB7Q37337898-49A5A43F-883B-440A-A97B-CE25C7481EFEQ37466336-3CD0CBC0-6419-4EEC-B15E-4B1EC2585EC0Q37935679-8204FEE3-BC25-4F73-BBF8-1B56F09F83B4Q38832105-25B58055-9C60-4158-92ED-E028ADDDC73DQ39422598-63EAF378-05E6-43CE-9572-9132DC7C4FC2Q39840103-FF7CC9A9-0477-4F3F-9C5B-3503D29904FCQ44878082-E9A4D777-CF83-4818-9158-D356BB4C67A1Q46439658-D483F05A-41C4-4575-9105-018769363DA8Q46463410-D89B7B2E-05E5-49B2-B70A-0118B4254F5A
P2860
The HER receptor family: a rich target for therapeutic development.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The HER receptor family: a rich target for therapeutic development.
@ast
The HER receptor family: a rich target for therapeutic development.
@en
type
label
The HER receptor family: a rich target for therapeutic development.
@ast
The HER receptor family: a rich target for therapeutic development.
@en
prefLabel
The HER receptor family: a rich target for therapeutic development.
@ast
The HER receptor family: a rich target for therapeutic development.
@en
P1476
The HER receptor family: a rich target for therapeutic development.
@en
P2093
Robert D Mass
P304
P356
10.1016/J.IJROBP.2003.09.093
P407
P577
2004-03-01T00:00:00Z